Ocuphire Pharma shareholders approve share increase to 125M, reject Lincoln Park issuance and officer exculpation

Opus Genetics, Inc.

Shareholders approved amendment to increase authorized common stock from 75M to 125M, effective June 12.
Shareholders rejected proposed issuance of shares to Lincoln Park Capital in excess of 19.99% of outstanding.
Shareholders rejected charter amendment to exculpate officers.
Board adopted amended bylaws with enhanced procedural rules for stockholder nominations and proposals.
All seven director nominees elected; Ernst & Young ratified as auditor; say-on-pay advisory approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.